Eli Lilly and Company (LLY)
| Market Cap | 662.23B |
| Revenue (ttm) | 49.00B |
| Net Income (ttm) | 11.11B |
| Shares Out | 897.74M |
| EPS (ttm) | 12.29 |
| PE Ratio | 60.02 |
| Forward PE | 29.41 |
| Dividend | $6.00 (0.81%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 6,112,336 |
| Open | 725.00 |
| Previous Close | 722.57 |
| Day's Range | 717.11 - 745.90 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 1,014.22 (+37.49%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,014.22, which is an increase of 37.49% from the latest price.
News
5 Alpha Generating Monsters
Any stock can generate alpha, but doing it consistently is rare. These 5 stocks have delivered alpha for 4 out of the last 5 years. Valuation is important, so I screen for it and eliminate overpriced ...
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
INDIANAPOLIS , May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatr...
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives
Eli Lilly And Co LLY on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal h...
Eli Lilly to acquire privately held SiteOne
Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS , May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc...
Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?
The supply of GLP-1 drugs has been increasing, but they're still expensive for most patients. Here are answers to some questions consumers have.
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INDIANAPOLIS , May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD...
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket costs ...
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
The authorization in Australia is for adult patients who are Apolipoprotein E- ε 4 heterozygotes or non-carriers INDIANAPOLIS , May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced...
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
The company delivered 45% revenue growth in Q1 2025, driven by ZEPBOUND and MOUNJARO's strong performance in the obesity and diabetes markets. ZEPBOUND outperformed Novo Nordisk's WEGOVY in terms of w...
Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in
The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the Danish pharmaceutical giant announced it would replace its long-serving chie...
3 Stocks That Will Profit From Trump's Drug Price Cut
On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Eli Lilly and Company (NYSE:LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,...
Trump calls out weight-loss drugs as target of price-cut push
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
20 stocks of companies showing excellent earnings-season trends even as the economy cools
With U.S. economic growth turning negative during the first quarter, this earnings season's results might shed some light on which companies may best weather the disruption brought about by President ...